Merck Enhances Immuno-Oncology Portfolio with Acquisition of cCAM Biotherapeutics

Dateline City: KENILWORTH, N.J. & MISGAV, Israel KENILWORTH, N.J. & MISGAV, Israel--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and cCAM Biotherapeutics announced today that the companies have signed a definitive agreement under which Merck will acquire cCAM Biotherapeutics, a privately held biopharmaceutical company focused on the discovery and development of novel cancer immunotherapies. Language: English Contact: Merck Media Relations:Pamela Eisele, 267-305-3558orAn Phan, 908-255-6325orMerck Investor Relations:Justin Holko, 908-740-1879orcCAM Investor/Media Relations:Tsipi Haitovsky, +972-525-989892 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Source: Merck.com - Corporate News - Category: Pharmaceuticals Tags: Oncology Newsroom Corporate News Latest News Source Type: news